Skip to main content
Clinical and Translational Medicine

Table 1 The affinities of the antibodies with the hPCSK9

From: The novel llama-human chimeric antibody has potent effect in lowering LDL-c levels in hPCSK9 transgenic rats

Ab ID

kon (1/Ms)

koff (1/s)

Rmax (RU)

Chi2 (RU2)

KD (nM)

VHH-B11

2.706 × 105

2.351 × 10−3

42.4

1.17

8.688

VHH-H12

0.7441 × 104

5.236 × 10−3

34.94

3.53

703.7

VHH-A6

1.543 × 104

4.468 × 10−4

15.40

0.334

28.97

VHH-G8

1.625 × 105

11.44 × 10−3

33.64

0.813

73.05

B11-Fc (25 °C)

1.872 × 106

1.288 × 10−3

24.71

0.693

0.6879

B11-Fc (1st week)

1.393 × 105

6.181 × 10−5

464.6

30.1

0.4438

B11-Fc (4th week)

1.362 × 105

9.116 × 10−5

457.4

25.3

0.6693

B11-Fc (7th week)

1.352 × 105

6.983 × 10−5

234.8

6.82

0.5166

B11-Fc (10th week)

1.304 × 105

6.523 × 10−5

161.9

3.22

0.5002

B11-Fc (13th week)

1.221 × 105

8.148 × 10−5

119.5

1.82

0.6673

B11-Fc (40 °C)

4.260 × 105

5.233 × 10−5

325.1

24.3

0.1228

  1. Ab ID represents the name of each antibody. kon (1/Ms) and koff (1/s) values, respectively represent the binding and dissociation levels of the VHH interacted with the hPCSK9. KD (M) was the measured affinity value acquired by the koff value divided by the kon value. Rmax (RU) represents the maximum binding response unit. Chi2 (RU2) represents the curve-fitting accuracy, generally ≤ 1/10 Rmax (RU). 25 °C/40 °C represents the reaction temperatures of the affinity determination assay by SPR. B11-Fc (xx week) represents their affinities which were detected at the preservation end of the 1st, 4th, 7th, 10th, and 13th weeks
Back to article page